We have demonstrated that Ep-CAM and CD44v6 provide prognostic information additional to the TNM stage in a large series of gastric cancer patients with well documented, prospectively collected data from a randomised trial (Bonenkamp et al, 1995, 1999). The gene discussed is EPCAM; the disease is gastric cancer.